Instructions
Select a story from the list below.
You will have the option to generate a social media post that conveys algorithmic dissentiment from that story.
Select a news article from below to generate a social media post.
| Article Title | Sentiment | Date | Summary | Stock | Id | Author |
|---|---|---|---|---|---|---|
| Article Title | Sentiment | Date | ||||
| US STOCKS-Wall St drops as Pfizer falls; presidential debate eyed | -10 | 2016-09-26 00:00:00 | * Pfizer falls after abandoning plan to split* U.S. presidential debate kicks off at 9:00 p.m. The S&P financial index fell 0.7 percent. The stock was the biggest drag on the S&P 500 healthcare index, which fell 0.98 percent, making it the biggest loser among the nine declining S&P sectors. The CBOE Market Volatility index, also known as Wall Street's "fear gauge", was up 1.5 percent, clocking its biggest percentage gain in nearly two weeks. The S&P 500 index showed two new 52-week highs and one new lows, while the Nasdaq recorded 31 new highs and 17 new lows. | PFE | {} | 39 |
| Pfizer Accused of Knowing Zoloft Posed Birth Risk | -50 | 2015-04-09 00:00:00 | “The science has never even suggested that birth defects were caused by Zoloft,” said Beth Wilkinson, one of the company’s lawyers. Families suing Pfizer over Zoloft contend the drugmaker ignored internal red flags about potential birth defects to protect billions in sales of the drug. Children with a septal heart defect must undergo surgery to close a hole in the wall of their heart. They contend the drugmaker should be held liable for failing to clearly warn doctors and patients that Zoloft posed an increased risk of birth defects in the drug’s label and promotional materials. The Zoloft internal report was introduced into evidence during the testimony of Robert Cabrera, a doctor at a University of Texas institute that studies birth defects. | PFE | {"Jef Feeley"} | 880 |
| Pfizer's Lipitor accused of causing serious side effects | -32 | 2006-06-08 00:00:00 | You would think that given the absolute size of Lipitor [sales], that if there were common severe side effects, they would have showed up. Mazzariello blames Lipitor for memory loss and muscle damage, said Krum, and he needs a cane to walk. However, the 3 percent growth for Lipitor sales in the first quarter of this year was "slower than anticipated," according to the company. News of the lawsuits "won't help Lipitor sales," regardless of their merit, said Les Funtleyder, analyst for Miller Tabak. Pfizer sued over alleged Lipitor side effectsTwo plaintiffs say cholesterol-cutting blockbuster caused nerve and muscle damage, memory loss. | PFE | {"Cnnmoney Com Staff Writer","Aaron Smith"} | 494 |
| Pfizer agrees to pay $60M to settle foreign bribery case | -19 | 2012-08-07 00:00:00 | The Justice Department said Pfizer’s cooperation and its internal probe of its operations worldwide helped the firm avoid criminal enforcement actions. By agreeing to help federal authorities with ongoing investigations of other firms, Pfizer “received a reduction in its penalties,” the Justice Department said. The SEC negotiated two civil settlements — one with Pfizer and another with Wyeth, which Pfizer purchased in 2009 — for a total of $45 million. No one at Pfizer headquarters knew of the bribery, regulators said. On Tuesday, Pfizer said that it alerted federal regulators to improper payments made by a Pfizer affiliate in Croatia immediately after learning of those payments in 2004. | PFE | {} | 672 |
| Pfizer settles foreign bribery case with U.S. government | -22 | 2012-08-07 17:21:38+00 | The 1977 Foreign Corrupt Practices Act makes it illegal for U.S. companies and foreign firms whose stock is traded in the United States to bribe government officials in foreign countries. The company also created programs under which government doctors could accumulate points based on the number of prescriptions they wrote for Pfizer products. In a parallel action, the U.S. Department of Justice said a Pfizer subsidiary, Pfizer H.C.P. Company employees bribed foreign officials to use Pfizer's products and boost prescriptions, the complaint said. Pfizer in 2004 became the first pharmaceutical company to volunteer information about past wrongdoing to the Justice Department, but the case has taken years to resolve. | PFE | {"Toni Clarke"} | 673 |
| Pfizer profit plunges, cholesterol drug dropped | -11 | 2016-11-01 23:36:00+00 | (AP Photo/Mark Lennihan, File) Photo: Mark Lennihan, Associated Press Pfizer profit plunges, cholesterol drug dropped 1 / 1 Back to GalleryDrugmaker Pfizer topped off a difficult third quarter with news that it’s scrapping a closely watched experimental cholesterol drug, partly due to expectations that insurers would limit access so much that it wouldn’t make enough money, a possible bad omen for the pharmaceutical industry. Pfizer profit plunges, cholesterol drug droppedPhoto: Mark Lennihan, Associated Press Image 1 of / 1 Caption Close Image 1 of 1 FILE - In this Monday, Nov. 23, 2015, file photo, a woman passes Pfizer's world headquarters, in New York. (AP Photo/Mark Lennihan, File) FILE - In this Monday, Nov. 23, 2015, file photo, a woman passes Pfizer's world headquarters, in New York. It forecast revenue of $52 billion to $53 billion, tweaked from its prior forecast of $51 billion to $53 billion. The mediocre results missed Wall Street expectations and Pfizer lowered the top end of its 2016 profit forecast. | PFE | {"Associated Press"} | 1045 |
| Pfizer Jury Told Zoloft Risks Known But Hidden From Patients | -39 | 2015-04-17 00:00:00 | Drug companies “can’t stay silent,” Hutson told the panel before it began deliberations in the case. That warning “never made it” into Zoloft’s U.S. warning label, Hutson told jurors Friday. “The FDA, doctors and independent researchers all came to the conclusion that Zoloft did not cause birth defects,” Wilkinson told the panel. Wilkinson countered that Pfizer officials included warnings about Zoloft use during pregnancy that were approved by the FDA. New York-based Pfizer pulled in about $2.6 billion in Zoloft sales in 2005, making it the most popular antidepressant on the market. | PFE | {"Jef Feeley","Tim Bross"} | 881 |
| Pfizer Sued by Australian Regulator Over Generic Lipitor | -7 | 2014-02-13 00:00:00 | Pfizer Inc.’s Australian unit was sued by the country’s competition regulator for misuse of market power relating to sales of its generic version of the Lipitor cholesterol drug. At the time Lipitor was prescribed to more than 1 million Australians with annual sales exceeding A$700 million ($625 million), according to the ACCC. Patent protection on Lipitor, the biggest selling prescription drug in Australia under the federal drug plan, expired in May 2012. The Australian Competition and Consumer Commission said it filed the lawsuit today in federal court in Sydney claiming Pfizer Australia Pty.’s deals with pharmacies in 2012 for the sale of atorvastatin breached competition rules. “Pfizer engaged in this conduct for the purpose of deterring or preventing competitors in the market for atorvastatin from engaging in competitive conduct,” ACCC Chairman Rod Sims said in a statement. | PFE | {"Joe Schneider"} | 493 |
| Doctors Without Borders Refuses Vaccines from Pfizer | -17 | 2016-10-14 08:00:00 | How has this system come to such a head that humanitarian doctors would refuse a million vaccines on principle? This week the medical-aid organization Doctors Without Borders refused a donation of one million vaccine doses from the pharmaceutical corporation Pfizer. Pfizer sells its PCV13 pneumonia vaccine under the name Prevnar 13. And this cost is the fundamental issue to Jason Cone, the executive director of Doctors Without Borders in the United States. One deal that Pfizer will talk about, even unprompted, is that with the Global Alliance for Vaccines and Immunization (GAVI), an organization that purchases vaccines in bulk on behalf of poor countries. | PFE | {"James Hamblin"} | 492 |
| Fighting drug maker health care fraud | -29 | 2010-10-11 00:00:00 | "She genuinely cares about public health and safety and is committed to prosecuting cases that will ensure that," said Sternberg. It is unlawful for drug companies to promote uses of medications that have not been approved for safety and effectiveness by the Food and Drug Administration (FDA). Officials also said Pfizer sent doctors on all-expense paid trips to resorts and paid kickbacks to influence their decision-making. " She called this "a deeply offensive notion" that corrupts the marketplace and could endanger patient health. The Pfizer investigation focused on the company's illegal marketing of four prescription drugs: Bextra, a painkiller; Geodon, an antipsychotic medication; Zyvox, an antibiotic; and Lyrica, a medication to treat nerve pain. | PFE | {"The Partnership For Public Service"} | 671 |
| Pfizer fined $106M for 2600% price hike on epilepsy drug | -20 | 2016-12-07 00:00:00 | Skip in Skip x Embed x Share Mylan is drawing fire for passing off massive price hikes for its EpiPen allergy treatment. Skip in Skip x Embed x Share Britain's competition watchdog has fined Pfizer a record $106 million for its role in ramping up the cost of an epilepsy drug by as much as 2,600 percent. (Photo: DON EMMERT, AFP/Getty Images)A British regulator on Wednesday hit U.S. pharmaceutical giant Pfizer with a record $106 million fine for imposing a 2600% price hike on an anti-epilepsy medication, the latest episode in widening public controversy over prescription drug prices. Pfizer was given 30 working days to four months to cut prices for the drug. The medication was "a loss making product" for the company, Pfizer said in a formal statement. | PFE | {"A M","Est December","Kevin Mccoy"} | 1115 |
| Britain fines Pfizer record $107 million for huge drug price hike | -11 | 2016-12-07 14:22:15+00 | REUTERS/Andrew Kelly/File photoLONDON Britain's competition watchdog has fined Pfizer (PFE.N) a record 84.2 million pounds ($107 million) for its role in ramping up the cost of an epilepsy drug by as much as 2,600 percent. The Competition and Markets Authority (CMA) also fined Flynn Pharma 5.2 million pounds for overcharging for phenytoin sodium capsules, following a dramatic price hike in 2012. "The previous highest fine of 58.5 million pounds was handed to British Airways (ICAG.L) in 2012 for colluding with rival Virgin Atlantic [VA.UL] on fuel surcharges. Flynn's chief executive David Fakes said punishing his company, which also plans to appeal, for selling phenytoin capsules for less than phenytoin tablets "beggars belief". As a result, annual spending on the capsules by Britain's National Health Service rose from 2 million pounds in 2012 to about 50 million in 2013. | PFE | {"Ben Hirschler"} | 1116 |
| Pfizer fined record £84.2m for overcharging NHS | -18 | None | Drugs giant Pfizer has been fined a record £84.2m by the UK's competition watchdog for overcharging the NHS for an anti-epilepsy drug. Pfizer then sold the UK rights to distribute the phenytoin sodium capsules to Flynn Pharma, which de-branded the drug. The government is seeking to tighten up regulation of generic drugs price rises. "Flynn Pharma said the CMA was "making a serious error" and that it would appeal in a bid to overturn the CMA's findings. NHS spending on the capsules, used by 48,000 UK patients, rose from £2m a year in 2012 to about £50m in 2013. | PFE | {"Business Reporter","Bbc News","Tom Espiner"} | 1117 |
| Could Pfizer's record fine for unfair prices change the industry's practices? | -10 | 2016-12-09 00:00:00 | It has also fined Flynn Pharma £5.2m, which is 10% of its worldwide turnover – the maximum possible fine. The government has realised that it does not have quite the kind of control that it thought it had over drug prices. Are drug companies often found to be up to anti-competitive practices? Earlier this year, GlaxoSmithKline was hammered by the CMA, effectively for paying off generic companies that wanted to make cheap copies of its best-selling antidepressant, paroxetine (Seroxat). This week Pfizer and Flynn Pharma were hit with maximum fines for hiking the price of an epilepsy drug by 2,600%. | PFE | {"Nils Pratley","Sarah Boseley"} | 1118 |
| Pfizer fined $2.3 billion for illegal marketing in off-label drug case | -31 | 2009-09-02 00:00:00 | Once the Food and Drug Administration approves drugs, doctors can prescribe them off-label for any use, but makers can't market them for anything other than approved uses. Pfizer subsidiary Pharmacia & Upjohn pleaded guilty to a felony violation for promoting off-label uses of Bextra, such as for pain relief after knee replacement surgery. At the FDA's request, Pfizer pulled Bextra off the market in April 2005 because its risks, including a rare, sometimes fatal, skin reaction, outweighed its benefits. Although Kopchinski worked three years as a financial adviser after leaving Pfizer, he says, "I pretty much depleted my 401(k). As part of the settlement, Pfizer (PFE) will pay a criminal fine of $1.195 billion, the largest criminal fine ever imposed in the USA for any matter, according to the Justice Department. | PFE | {"Usa Today","Rita Rubin"} | 70 |